This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, G.
Right arrow Articles by Aiyar, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, G.
Right arrow Articles by Aiyar, A.

 Previous Article  |  Next Article 

Journal of Virology, May 2009, p. 4227-4235, Vol. 83, No. 9
0022-538X/09/$08.00+0     doi:10.1128/JVI.02578-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Optimal Transactivation by Epstein-Barr Nuclear Antigen 1 Requires the UR1 and ATH1 Domains{triangledown}

Gyanendra Singh,1 Siddhesh Aras,2 Arnold H. Zea,1,2 Shahriar Koochekpour,1,2 and Ashok Aiyar1,2*

Stanley S. Scott Cancer Center,1 Department of Microbiology, Louisiana State University Health Sciences Center, New Orleans, Louisiana 701122

Received 14 December 2008/ Accepted 11 February 2009

Epstein-Barr nuclear antigen 1 (EBNA1) is essential for Epstein-Barr virus to immortalize naïve B cells. EBNA1 transactivates viral promoters for genes that are necessary for immortalization when it is bound to a cluster of 20 cognate binding sites, termed the family of repeats. A region of EBNA1 from amino acids (aa) 40 to 89, termed linking region 1 (LR1), has been identified previously as being sufficient for transactivation. LR1 contains two domains that are conserved in the EBNA1 orthologs of other gamma herpesviruses. The first of these, termed unique region 1 (UR1), corresponds to aa 65 to 89 of EBNA1. UR1 is necessary for transactivation and contains a conserved recognition site for cyclic AMP-dependent protein kinase (PKA), corresponding to serine 78 of EBNA1. We have pharmacologically modulated PKA activity to determine if PKA controls EBNA1's ability to transactivate. Our results indicate that PKA activators and inhibitors do not affect transactivation by EBNA1. In addition, site-directed mutagenesis demonstrates that transactivation is not influenced by the phosphorylation status of serine 78 in the UR1 domain. The second conserved domain within LR1 is a glycine-arginine repeat, corresponding to aa 40 to 54 of EBNA1. This domain, termed ATH1, functions as an AT-hook, a DNA-binding motif found in architectural transcription factors such as HMGA1a. We demonstrate that deletion of the ATH1 domain decreases EBNA1 transactivation ability, which is consistent with a transcriptional role for ATH1. Furthermore, transactivation is restored when ATH1 is replaced by equivalent AT-hook motifs from HMGA1a. Our data strongly indicate a role for AT-hooks in EBNA1's ability to transactivate, a function necessary for EBV to immortalize naïve B-cells.

* Corresponding author. Mailing address: LSU Health Sciences Center, Box P6-1, MEB, 1901 Perdido Street, New Orleans, LA 70112. Phone: (504) 568-4072. Fax: (504) 568-2918. E-mail: aaiyar{at}lsuhsc.edu

{triangledown} Published ahead of print on 25 February 2009.

Journal of Virology, May 2009, p. 4227-4235, Vol. 83, No. 9
0022-538X/09/$08.00+0     doi:10.1128/JVI.02578-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»